MVP chemotherapy (mitomycin C, vindesine or vinblastine, cisplatin) is one of the most commonly used regimens for advanced non-small cell lung cancer (NSCLC). Experimental data suggest a synergistic cytotoxic activity of alpha-interferon (α-IFN) when combined with cisplatin, mitomycin C, and vinca alkaloids. In an effort to improve MVP chemotherapy activity, we have combined this regimen with α-IFN.
Patients and methods
Thirty-five patients with advanced NSCLC (19 stage IV) were treated with the MVP regimen (mitomycin C, 8 mg/m2; vindesine, 3 mg/m2; cisplatin, 75 mg/m2, all on day 1) plus α-2a-IFN, 3×106 U im from day 1 to 7. The cycles were repeated every 28 days.
Results
There were no complete responses and 18 partial responses, for an overall response rate of 51%. Median time to treatment failure was 6 months (range, 1-18), and median survival was 9.5 months (range, 1-32). WHO grade 3 toxicity was recorded in up to 8% of patients, flu-like syndrome was a common complaint; one toxic death occurred.
Conclusions
The combination yielded a level of response comparable to that of other cisplatin-based regimens. Larger randomized trials are needed to assess the role of α-IFN combined with chemotherapy in advanced NSCLC.
AaproM.S., AlbertsD.S., SalmonS.E.: Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay.Cancer Chemother. Pharmacol., 10: 161–166, 1983.
2.
Ardizzoni A., Salvati F., Rosso R., Bruzzi P., Rubagotti A., Pennucci M.C., Mariani G.L., De Marinis F., Pallotta G., Antilli A., Crociani A.M., Rinaldi M., Tonachella R., Fioretti M., Barbera S., Mantellini E., Soresi E., Pastorino G., Belli M., Ferrara G., Venturini M., Scagliotti G., Santi L. for the Italian Lung Cancer Task Force: Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer.Cancer, 72: 2929–2935, 1993.
3.
BowmanA., FergussonR.J., AllanS.G., StewartM.E., GregorA., CornbleetM.A., GreeningA.P., CromptonG.K., LeonardR.C., SmythJ.F.: Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer: a phase II study.Ann. Oncol., 1: 351–353, 1990.
4.
CarmichaelJ., FergussonR.J., WolfC.R., BalkwillF.R., SmythJ.F.: Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts.Cancer Res., 46: 4916–4920, 1986.
5.
FukuokaM., NegoroS., MasudaN., KusunokiY., MatsuiK., RyuS., TakifujiN., KudohS., TakadaM.: Mitomycin C, vindesine, and cisplatin in advanced non-small cell lung cancer. A phase II study.Am. J. Clin. Oncol., 15: 18–22, 1992.
6.
GrallaR.J., KrisM., PotanovichL., MarksL.A., HeelanR.T.: Enhancing the safety and efficacy of the MVP regimen (mitomycin + vinblastine + cisplatin) in 100 patients with inoperable non-small cell lung cancer (NSCLC). Proc.Am. Soc. Clin. Oncol., 8: 227, 1989.
7.
GrunbergS.M., KempfR.A., ItriL.M., VenturiC.L., BoswellW.D.Jr., MitchellM.S.: Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma.Cancer Treat. Rep., 69: 1031–1032, 1985.
8.
HalmeM., MaasiltaP.K., PyrhönenS.O., MattsonK.V.: Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer - a randomized study.Eur. J. Cancer, 30A: 11–15, 1994.
9.
JossR.A., BurkiK., DalquenP., SchatzmannE., LeyvrazS., CavalliF., LudwigC., SiegenthalerP., AlbertoP., StahelR., HoldenerE.E., SennH.: Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer.Cancer, 65: 2426–2434, 1990.
10.
KrisM.G., GrallaR.J., WertheimM.S., KelsenD.P., O'ConnellJ.P., BurkeM.T., FioreJ.J., CibasI.R., HeelanR.T.: Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.Cancer Treat. Rep., 70: 1091–1096, 1986.
11.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
12.
MountainC.F.: A new international staging system for lung cancer.Chest,89(Suppl. 4): 225–233, 1986.
13.
OlesenB.K., ErnstP., NissenM.H., HansenH.H.: Recombinant interferon α (IFN-rα) therapy of small cell and squamous cell carcinoma of the lung: a phase II study.Eur. J. Cancer Clin. Oncol., 23: 987–989, 1987.
14.
RoseliR., CarlesJ., ArizaA., MorenoI., RibellesN., SolanoV., PellicerI., BarnadasA., AbadA.: A phase II study of days 1 and 8 cisplatin and recombinant alpha-2b interferon in advanced non-small cell lung cancer.Cancer, 67: 2448–2453, 1991.
15.
RuckdeschelJ.C.: Is chemotherapy for metastatic non-small cell lung cancer “worth it”? J.Clin. Oncol., 8: 1293–1296, 1990.
16.
RuckdeschelJ.C., FinkelsteinD.M., MasonB.A., CreechR.H.: Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation V - a randomized comparison of four cisplatin-containing regimens.J. Clin. Oncol., 3: 72–79, 1985.
17.
SchillerJ.H., StorerB., DreicerR., RosenquistD., FrontieraM., CarboneP.P.: Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung.J. Natl. Cancer Inst., 81: 1739–1743, 1989.
18.
SklarinN.T., ChahinianA.P., FeuerE.J., LahmanL.A., SzrajerL., HollandJ.F.: Augmentation of activity of cis-diamminedichloroplatinum (II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice.Cancer Res., 48: 64–67, 1988.
19.
SmythJ., FergussonR., StewartM., CornbleetM., GregorA., LeonardR.: Alpha interferon potentiates cisplatin in patients with non-small cell lung cancer (NSCLC). Proc.Am. Soc. Clin. Oncol., 7: A777, 1988.
WelanderC.E., MorganT.M., HomesleyH.D., TrottaP.P., SpiegelR.J.: Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay.Int. J. Cancer, 35: 721–729, 1985.
22.
WelanderC.E.: Overview of preclinical and clinical studies of interferon alpha-2b in combination with cytotoxic drugs.Invest. New Drugs, Suppl5: 47–59, 1987.
